Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields; Erin K. McCreary; Rachel V. Marini; Ellen G. Kline; Chelsea E. Jones; Binghua Hao; Liang Chen; Barry N. Kreiswirth; Yohei Doi; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciz1131

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields, Erin K. McCreary, Rachel V. Marini, Ellen G. Kline, Chelsea E. Jones, Binghua Hao, Liang Chen, Barry N. Kreiswirth, Yohei Doi, Cornelius J. Clancy, M. Hong Nguyen

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

77 被引用数 (Scopus)

抄録

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

本文言語	英語
ページ（範囲）	667-671
ページ数	5
ジャーナル	Clinical Infectious Diseases
巻	71
号	3
DOI	https://doi.org/10.1093/cid/ciz1131
出版ステータス	出版済み - 01-08-2020
外部発表	はい

All Science Journal Classification (ASJC) codes

微生物学（医療）
感染症

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1093/cid/ciz1131

他のファイルとリンク

引用スタイル

@article{4fd3c07041154441bfde9a924498c076,

title = "Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections",

abstract = "Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.",

keywords = "KPC, Meropenem, P orin, Resistance, Vaborbactam",

author = "Shields, {Ryan K.} and McCreary, {Erin K.} and Marini, {Rachel V.} and Kline, {Ellen G.} and Jones, {Chelsea E.} and Binghua Hao and Liang Chen and Kreiswirth, {Barry N.} and Yohei Doi and Clancy, {Cornelius J.} and Nguyen, {M. Hong}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2020",

month = aug,

day = "1",

doi = "10.1093/cid/ciz1131",

language = "English",

volume = "71",

pages = "667--671",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

AU - Shields, Ryan K.

AU - McCreary, Erin K.

AU - Marini, Rachel V.

AU - Kline, Ellen G.

AU - Jones, Chelsea E.

AU - Hao, Binghua

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Doi, Yohei

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

N1 - Publisher Copyright: © The Author(s) 2019.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

AB - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

KW - KPC

KW - Meropenem

KW - P orin

KW - Resistance

KW - Vaborbactam

UR - http://www.scopus.com/inward/record.url?scp=85088848147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088848147&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz1131

DO - 10.1093/cid/ciz1131

M3 - Article

C2 - 31738396

AN - SCOPUS:85088848147

SN - 1058-4838

VL - 71

SP - 667

EP - 671

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

抄録

All Science Journal Classification (ASJC) codes

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル